drugset / Trial / NCT02540538

Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders

NCT02540538

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to determine whether the HBAI20 vaccine is safe and more immunogenic than the HBVaxPro-10µg in people who have never been vaccinated with a hepatitis B vaccine and in people who have been vaccinated 6 times with hepatitis B vaccine but do not have a protective anti hepatitis B antibody titer.

Timeline

Start
2015-09
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject HBAI20 Vaccine
Comparator HBVAXPRO Vaccine 10 ug